Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions3-Year Results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) Trial
Henning Kelbæk, MD*,*,
Lene Kløvgaard, RN*,
Steffen Helqvist, MD*,
Jens F. Lassen, MD ,
Lars R. Krusell, MD,
Thomas Engstrøm, MD*,
Hans E. Bøtker, MD,
Erik Jørgensen, MD*,
Kari Saunamäki, MD*,
Samir Aljabbari, MD*,
Per Thayssen, MD ,
Anders Galløe, MD ,
Gunnar V.H. Jensen, MD¶ and
Leif Thuesen, MD
* Rigshospitalet, Copenhagen, Denmark
Skejby Sygehus, Skejby, Denmark
Odense Universitetshospital, Odense, Denmark
Gentofte Hospital, Gentofte, Denmark
¶ Roskilde Hospital, Roskilde, Denmark.
View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 MACE Within 3 Years After Stent Implantation
Frequency of major adverse cardiac events (MACE) (i.e., death, myocardial infarction, and target lesion revascularization [TLR]), occurring 3 years after implantation of sirolimus-eluting stents (SES) and bare-metal stents (BMS). TVR = target vessel revascularization.
|
|
View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Subgroup Analysis for the 3-Year Rate of MACE
Odds ratios for the occurrence of MACE in the SES and BMS groups. CI = confidence intervals; CX = circumflex artery; LAD = left anterior descending artery; RCA = right coronary artery; other abbreviations as in Figure 1.
|
|
|
